UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 75

Sortiert nach

GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study

Journal of viral hepatitis, 2016-08, Vol.23 (8), p.614-622

2016

Volltextzugriff (PDF)

P0901 : The pan-genotypic NS3/4A protease inhibitor GS-9857 demonstrates potent antiviral activity in patients infected with HCV genotype 1, 2, 3 or 4 in a 3-day monotherapy study

Journal of hepatology, 2015-04, Vol.62, p.S682-S682

2015

Volltextzugriff (PDF)

1206 PHARMACODYNAMICS OF ORAL TLR-7 AGONIST GS-9620 IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C

Journal of hepatology, 2013-04, Vol.58, p.S490-S490

2013

Volltextzugriff (PDF)

Characteristics of breakthrough cancer pain in patients treated with fentanyl sublingual tablets: An analysis of two phase III trials

Journal of clinical oncology, 2011, Vol.29 (15_suppl), p.e19593-e19593

2011

Volltextzugriff (PDF)

Tolerability of sublingual fentanyl tablets for the treatment of breakthrough cancer pain in patients aged ≥65 years: pooled analysis from 2 clinical trials

The journal of pain, 2011, Vol.12 (4), p.P51-P51

2011

Volltextzugriff (PDF)

Human Factors Validation of a Wearable, On-Body Infusor for Subcutaneous Administration of Furosemide

Medical devices (Auckland, N.Z.), 2024-06, Vol.17, p.229-235

2024

Volltextzugriff (PDF)

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

The New England journal of medicine, 2009-08, Vol.361 (8), p.745-755

2009

Volltextzugriff (PDF)

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

The Lancet (British edition), 2009-02, Vol.373 (9662), p.473-481

2009

Volltextzugriff (PDF)

Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain

Current medical research and opinion, 2009-12, Vol.25 (12), p.2877-2885

2009

Volltextzugriff (PDF)

321 A RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO AND NAPROXEN CONTROLLED, MULTICENTER PHASE 3 STUDY OF NAPROXCINOD IN SUBJECTS WITH OSTEOARTHRITIS OF THE KNEE: EFFICACY RESULTS FOLLOWING 13-WEEK TREATMENT

Osteoarthritis and cartilage, 2009, Vol.17, p.S171-S172

2009

Volltextzugriff (PDF)

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2019-02, Vol.393 (10173), p.778-790

2019

Volltextzugriff (PDF)

Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data

The American journal of gastroenterology, 2010-07, Vol.105 (7), p.1574-1582

2010

Volltextzugriff (PDF)

F609 PATIENT SATISFACTION DURING TREATMENT WITH SUBLINGUAL FENTANYL FOR BREAKTHROUGH CANCER PAIN

European journal of pain supplements, 2011-09, Vol.5 (1), p.171-172

2011

Volltextzugriff (PDF)

S618 TOLERABILITY OF SUBLINGUAL FENTANYL TABLETS FOR BREAKTHROUGH CANCER PAIN IN PATIENTS AGED ≥ 65 YEARS: POOLED ANALYSIS OF TWO CLINICAL TRIALS

European journal of pain supplements, 2011-09, Vol.5 (1), p.274-275

2011

Volltextzugriff (PDF)

Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

European heart journal, 2003-04, Vol.24 (8), p.717-728

2003

Volltextzugriff (PDF)

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2011-04, Vol.13 (4), p.348-356

2011

Volltextzugriff (PDF)

Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain

Current medical research and opinion, 2011-03, Vol.27 (3), p.519-530

2011

Volltextzugriff (PDF)

Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months

Clinical gastroenterology and hepatology, 2010-07, Vol.8 (7), p.600-609

2010

Volltextzugriff (PDF)

Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study

Atherosclerosis, 2014-01, Vol.232 (1), p.86-93

2014

Volltextzugriff (PDF)

A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge X 6 mm needle versus a 29 gauge X 12.7 mm needle in obese patients with diabetes mellitus

Clinical therapeutics, 2004-10, Vol.26 (10), p.1663-1678

2004

Volltextzugriff (PDF)

Repaglinide versus nateglinide monotherapy: A randomized, multicenter study

Diabetes care, 2004-06, Vol.27 (6), p.1265-1270

2004

Volltextzugriff (PDF)

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2010-07, Vol.12 (7), p.604-612

2010

Volltextzugriff (PDF)

Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial

The American heart journal, 2002-12, Vol.144 (6), p.1036-1043

2002

Volltextzugriff (PDF)

Aqueous Macrophages Contribute to Conserved CCL2 and CXCL10 Gradients in Uveitis

Ophthalmology science (Online), 2024-07, Vol.4 (4), p.100453-100453, Article 100453

2024

Volltextzugriff (PDF)

Clinicomolecular Identification of Conserved and Individualized Features of Granulomatous Uveitis

Ophthalmology science (Online), 2021-03, Vol.1 (1), p.100010, Article 100010

2021

Volltextzugriff (PDF)

1 – 25 von 75

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(68)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(52)
Life Sciences & Biomedicine
(49)
Female
(38)
Humans
(38)
Male
(35)
Middle Aged
(31)
Adult
(25)
Biological And Medical Sciences
(21)
Aged
(18)
Medical Sciences
(17)
Double-Blind Method
(16)
Treatment Outcome
(13)
Animals
(11)
General & Internal Medicine
(11)
Medicine, General & Internal
(11)
Young Adult
(11)
Diabetes Mellitus, Type 2 - Drug Therapy
(8)
Pharmacology. Drug Treatments
(8)
Aged, 80 And Over
(7)
Clinical Trials
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study

P0901 : The pan-genotypic NS3/4A protease inhibitor GS-9857 demonstrates potent antiviral activity in patients infected with HCV genotype 1, 2, 3 or 4 in a 3-day monotherapy study

1206 PHARMACODYNAMICS OF ORAL TLR-7 AGONIST GS-9620 IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C

Characteristics of breakthrough cancer pain in patients treated with fentanyl sublingual tablets: An analysis of two phase III trials

Tolerability of sublingual fentanyl tablets for the treatment of breakthrough cancer pain in patients aged ≥65 years: pooled analysis from 2 clinical trials

Human Factors Validation of a Wearable, On-Body Infusor for Subcutaneous Administration of Furosemide

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain

321 A RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO AND NAPROXEN CONTROLLED, MULTICENTER PHASE 3 STUDY OF NAPROXCINOD IN SUBJECTS WITH OSTEOARTHRITIS OF THE KNEE: EFFICACY RESULTS FOLLOWING 13-WEEK TREATMENT

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data

F609 PATIENT SATISFACTION DURING TREATMENT WITH SUBLINGUAL FENTANYL FOR BREAKTHROUGH CANCER PAIN

S618 TOLERABILITY OF SUBLINGUAL FENTANYL TABLETS FOR BREAKTHROUGH CANCER PAIN IN PATIENTS AGED ≥ 65 YEARS: POOLED ANALYSIS OF TWO CLINICAL TRIALS

Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain

Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months

Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study

A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge X 6 mm needle versus a 29 gauge X 12.7 mm needle in obese patients with diabetes mellitus

Repaglinide versus nateglinide monotherapy: A randomized, multicenter study

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes

Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial

Aqueous Macrophages Contribute to Conserved CCL2 and CXCL10 Gradients in Uveitis

Clinicomolecular Identification of Conserved and Individualized Features of Granulomatous Uveitis

Suchergebnisse filtern